関連する実験動画
Updated: Jul 8, 2026

09:40
Magnetic Adjustment of Afterload in Engineered Heart Tissues
Published on: May 5, 2020
ミエロペロキシダースによって生成された酸化物質は,左心室の改造を調節するが,心筋梗塞後の心臓発作の大きさは調節しない
Nikolay Vasilyev1, Timothy Williams, Marie-Luise Brennan
1Department of Cell Biology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Circulation
|November 4, 2005
まとめ
心臓発作 (心筋梗塞) の後の炎症は,心臓の機能を悪化させる. ミエロペロキシダース (MPO) によって生成されたアルデヒドは,心臓発作の大きさではなく,不良な心臓の改造と左心室機能の障害を誘導します.
科学分野:
- 心血管生物学 心血管生物学
- 炎症の研究 炎症の研究
- オキシダティブ・ストレスは,
背景:
- 心筋梗塞 (MI) 以後の炎症は,左心室 (LV) の機能とアウトカムが悪いことと関連しています.
- 炎症がLV機能に影響する正確なメカニズム,特に心臓発作のサイズとLVの改造に関する正確なメカニズムは不明のままです.
- 酸化ストレスは細胞毒性アルデヒドを生成し,潜在的に改造と心臓発作のサイズに影響を与える可能性があります.
研究 の 目的:
- MI中に細胞毒性アルデヒドを生成するミエロペロキシダース (MPO) の役割を調査する.
- MPOによって生成された酸化物質が,心筋梗塞の大きさや,心筋梗塞の再構成に及ぼす機能的影響を,イシュケミア/再輸血型心筋梗塞モデルで決定する.
主な方法:
- アミノ酸のMPO酸化製品が,血管細胞の細胞毒性について評価された.
- マススペクトロメトリを使用して,ネズミのMIの心筋組織におけるMPO生成アルデヒド (フォーマルアルデヒド,アクロレイン) を特定しました.
- 脊髄膜の再構築と機能の比較 MPO-nullとワイルド型のマウスで,イシュケミア/再輸血による損傷の後に.
主要な成果:
- グリシンとスレオニンのMPO酸化により,最も細胞毒性のあるアルデヒド (フォーマルアルデヒドとアクロライン) が生成された.
- ミエロペロキシダース (MPO) は,MI心筋組織におけるこれらのアルデヒドの主要な酵素源として確認されました.
- MPOゼロのマウスは,心臓発作の大きさの違いはなく,野生型のマウスと比較して,LVの拡張が有意に減少した (35.1%) とLVの機能が改善された (52.2%) を示しました.
結論:
- 心臓発作のサイズとLVリモデルの炎症効果は異なっている.
- MPOによって生成された酸化物質は,心筋梗塞後の心筋縮に有意な影響を及ぼさない.
- MPOによって生成される酸化物質は,心筋梗塞の後にLVの改造と機能に悪影響を及ぼします.
関連する概念動画
Anatomy of the Heart
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

